Merocyanine derivatives as theranostic agents for cognitive improvement and real-time imaging of amyloid-β in APP/PS1 transgenic mice
Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy · 2026
DOI: 10.1016/j.saa.2026.128458 ↗Kurz gefasst
Fachartikel in der Zeitschrift Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, 2026. Verfasst von Xinrui Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Bioengineering, Zhuhai Campus of Zunyi Medical University, Zhuhai 519090, China. Hauptthemen laut MEDLINE: Amyloid beta-Peptides, Alzheimer Disease, Benzopyrans, Indoles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Amyloid-β (Aβ) is widely recognized as a biomarker for the diagnosis and treatment of Alzheimer's Disease (AD). In our previous work, a series of merocyanine fluorescent probes were designed, synthesized and evaluated for the imaging of Aβ plaques. Here, we further identified the representative probe D4, which not only demonstrates the characteristics of a highly sensitive fluorescent probe for real-time imaging of Aβ content in the brain of APP/PS1 mice, but also exhibited the ability to treat AD, including inhibition of Aβ aggregation (inhibition rate: 89.5%), antioxidant activity (3.4 times that of Trolox); AChE inhibitory activity (IC50 = 0.5 ± 0.0 μM) and the capacity to cross the BBB (Pe = 8.6 ± 0.7). Additionally, D4 dramatically attenuates Aβ-induced SH-SY5Y cell death by preventing the generation of ROS, and intravenous administration of 0.5 mg/kg D4 for 15 days significantly improved the cognitive ability of 7-month-old APP/PS1 mice by protecting hippocampal and cortex neurons from necrosis, attenuating oxidative stress in the hippocampus and cortex, and reducing Aβ burden deposition. These findings strongly suggest that D4 owns a high theranostic potential for treating AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Bioengineering, Zhuhai Campus of Zunyi Medical University, Zhuhai 519090, China.
- School of Bioengineering, Zhuhai Campus of Zunyi Medical University, Zhuhai 519090, China. Electronic address: chendaoyuan@zmuzh.edu.cn.
- Department of Radiology, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital/Harvard Medical School, Charlestown, Boston, MA, USA. Electronic address: jyan16@mgh.harvard.edu.cn.
- School of Bioengineering, Zhuhai Campus of Zunyi Medical University, Zhuhai 519090, China. Electronic address: xiachl@zmu.edu.cn.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Li, X., Li, S., Su, J., Zheng, F., Li, S., Zhao, X., Chen, D., Yan, J., & Xia, C. (2026). Merocyanine derivatives as theranostic agents for cognitive improvement and real-time imaging of amyloid-β in APP/PS1 transgenic mice. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy. https://doi.org/10.1016/j.saa.2026.128458
Vancouver
Li X, Li S, Su J, Zheng F, Li S, Zhao X, et al. Merocyanine derivatives as theranostic agents for cognitive improvement and real-time imaging of amyloid-β in APP/PS1 transgenic mice. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy. 2026. doi:10.1016/j.saa.2026.128458
BibTeX
@article{Li2026,
author = {Li, Xinrui and Li, Shun and Su, Junyi and Zheng, Faqiong and Li, Shuanglong and Zhao, Xiujuan and Chen, Daoyuan and Yan, Jinwu and Xia, Chunli},
title = {Merocyanine derivatives as theranostic agents for cognitive improvement and real-time imaging of amyloid-β in APP/PS1 transgenic mice},
journal = {Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy},
year = {2026},
doi = {10.1016/j.saa.2026.128458}
}
EUVIMED